... San Antonio Breast Cancer Symposium ('SABCS”) today, Thursday, December 11 ... Celcuity is a clinical-stage biotechnology company pursuing development ...
News
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the ... - The Manila Times
- Pfizer Builds Case for Tukysa as 'New Standard Regimen' in First-Line Metastatic Breast Cancer
Results, announced Wednesday and presented at the 48th San Antonio Breast Cancer Symposium (SABCS), showed the Tukysa-based combo cut the risk of ...
- NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly ... - Rutland Herald
... San Antonio Breast Cancer Symposium (SABCS 2025) being held December 9 ... NiKang Therapeutics is a clinical-stage biotech company focused on ...
- NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and ...
... San Antonio Breast Cancer Symposium (SABCS 2025) being held December 9 ... Biotechnology. NiKang Therapeutics Inc. Logo. NiKang Therapeutics ...
- Intensity Therapeutics, Inc. to Present Two Posters at the 2025 - GuruFocus
... Biotechnology NAS:INTS. Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium. Author's Avatar.